Flossbach Von Storch SE Sells 147,212 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Flossbach Von Storch SE trimmed its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 3.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,259,631 shares of the company's stock after selling 147,212 shares during the period. BioNTech makes up about 1.7% of Flossbach Von Storch SE's portfolio, making the stock its 21st largest holding. Flossbach Von Storch SE owned 1.78% of BioNTech worth $387,882,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BNTX. Jones Financial Companies Lllp increased its holdings in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after buying an additional 246 shares in the last quarter. Allianz SE bought a new position in shares of BioNTech in the fourth quarter valued at $90,000. Goodman Advisory Group LLC bought a new position in shares of BioNTech in the first quarter valued at $105,000. Tower Research Capital LLC TRC increased its holdings in shares of BioNTech by 61.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock valued at $214,000 after buying an additional 713 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its holdings in shares of BioNTech by 7.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock valued at $221,000 after buying an additional 128 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BNTX has been the topic of several research reports. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Citigroup reissued a "buy" rating and set a $140.00 target price (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. The Goldman Sachs Group began coverage on shares of BioNTech in a research note on Thursday, May 29th. They set a "neutral" rating and a $110.00 target price on the stock. Morgan Stanley set a $133.00 target price on shares of BioNTech and gave the company an "overweight" rating in a research note on Thursday. Finally, Truist Financial reissued a "buy" rating and set a $155.00 target price (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $137.91.

BioNTech Stock Down 0.9%

Shares of NASDAQ BNTX traded down $1.03 during mid-day trading on Friday, reaching $112.89. The company had a trading volume of 521,908 shares, compared to its average volume of 943,543. BioNTech SE Sponsored ADR has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. The stock has a market capitalization of $27.14 billion, a PE ratio of -33.20 and a beta of 1.29. The stock's 50 day moving average is $103.56 and its 200-day moving average is $106.81.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.